Strategic Investment Novan has recently secured funding and potential acquisition activity involving Ligand, indicating heightened investor interest and a potential need for strategic partnerships to accelerate product development and commercialization.

Cash Preservation Historic headcount reductions and DIP financing suggest the company is prioritizing cash efficiency; sales opportunities could focus on cost-effective, high-ROI collaborations, licensing, or services that do not require large upfront investments.

Dermatology Focus With a dermatology-centric history, EPI Health assets, and licenses related to RHOFADE, there is a clear avenue for partnerships around dermatology manufacturing, regulatory support, or co-development in skin-care and prescription products.

Outsourced Capabilities The small team size implies potential reliance on external partners for clinical, regulatory, and manufacturing needs; offering CRO/CMO services, regulatory consulting, or trial support could meet critical operational gaps.

Strategic Licensing Existing and past licensing relationships with Sato and others point to a receptiveness for collaboration; targeted BD outreach around licensing, co-development, and regional commercialization rights may align with their strategic goals.